Administration of Single High Dose Letrozole for Ovulation Induction

Status Completed

Clinical Trial Summary

Letrozole is considered an established treatment for ovulation induction.The most common protocol is daily dose of 2.5-7.5 mg starting day 3-5 of the cycle for 5 days.Another described protocol is single high dose 20mg Letrozole given on day 3 of the cycle. Our aim is to compare the single high dose Letrozole protocol to daily low dose protocol.

Clinical Trial Description

Pre-study screening will be conducted before the enrolment in the study, routine fertility assessment: Physical history including fertility and fertility treatment history. Laboratory tests-cycle day 3 hormonal profile (Estradiol, Luteinizing hormone, Follicular stimulating hormone, progesterone), cycle day 3 antral follicular count. Pregnancy will be excluded by Human chorionic gonadotropin test at day 3 of the cycle, before starting the fertility treatment. Polycystic syndrome (PCOS) patients will be defined according to Rotterdam criteria 2003. A prospective randomized clinical trial. PCOS patients who require induction of ovulation will prospectively randomized into two groups: 1. Single 20 mg dose of Letrozole on day 3 of the menstrual cycle. Monitoring for response will include the usual measurements of serum Estradiol (E2), Follicle stimulating hormone (FSH), Luteinizing Hormone (LH), Progesterone (P) and transvaginal ultrasound for follicular count and endometrial thickness measurement. First monitoring will be on day 7 of the cycle and the rest of the monitoring will be determined according to response. 2. Daily dose of Letrozole 2.5 mg starting day 3 for 5 days. Monitoring for response will include serum Estradiol (E2), Follicule stimulating hormone (FSH), Luteinizing Hormone (LH ), Progesterone (P) and transvaginal ultrasound for follicular count and endometrial thickness measurement. First day of monitoring will be on day 7 and the rest of monitoring will be determined according to response. Statistical Analysis - Primary Endpoint Analysis: Sample Size Selection In order to prove non-inferiority with significance level (alpha) 5% and power of 90%, standard deviation of outcome 1, and noninferiority limit 1; the sample size needed is 36 patients in both groups. Calculation based on Jolious SA formula.(7) - Planned Analysis Primary Outcome Analysis: Comparison of the number of follicle >15 mm at day of ovulation Secondary Outcome Analysis: Pregnancy rate Comparison between the two groups Estradiol levels at day of ovulation triggering Ovarian hyperstimulation syndrome Clinical pregnancy rate Statistical analysis : The various outcome measures will be expressed as numbers and rates. The Student t test, χ2 test and analysis of variance will be used where appropriate to analyze the various data among the study groups. P value less than .05 will be considered statistically significant. ;

Study Design

Related Conditions & MeSH terms

Anovulation

Clinical Trial Details

NCT number	NCT02703649
Study type	Interventional
Source	Mount Sinai Hospital, Canada
Contact
Status	Completed
Phase	Phase 4
Start date	March 2016
Completion date	July 31, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01653743` - Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women	Phase 3
Completed	`NCT00327366` - Effect of Bright Light on Sex Hormones and Ovulation in Humans	N/A
Not yet recruiting	`NCT02551367` - Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Poly Cystic Ovary Syndrome ( PCOS )	Phase 2
Completed	`NCT01923194` - Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females	Phase 3
Completed	`NCT01008319` - Traditional Clomiphene Citrate Administration vs. Stair-step Approach	Phase 3
Completed	`NCT00239603` - Efficacy Study of the OV-Watch™ Personal Fertility Monitor for Women Using Clomiphene Citrate.	Phase 4
Recruiting	`NCT02309047` - The Cycle Disturbances, OLigomenorrhea and Amenorrhea (COLA) Study & Biobank
Completed	`NCT03252223` - Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS	Phase 4
Completed	`NCT00492882` - Study of Mechanisms of Anovulation in Polycystic Ovary Syndrome	Phase 4
Completed	`NCT02335879` - Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation	Phase 3
Completed	`NCT00471523` - Treatment of Anovulatory Infertility in PCOS Patients	Phase 4
Completed	`NCT00213148` - Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction	Phase 2
Completed	`NCT03018314` - Serum Kisspeptin Levels in Infertile Women	N/A
Completed	`NCT02710981` - Sildenafil Vaginal Gel Co-treatment With Clomiphene Citrate in Infertile Women With Thin Endometrium	N/A
Recruiting	`NCT02186782` - Concomitant CC and E2 Versus CC Alone in Ovulation Induction	Phase 4
Not yet recruiting	`NCT00665171` - Whole Genome Analysis for the Detection of Key Genes in the Polycystic Ovary Syndrome	N/A
Withdrawn	`NCT03155828` - Using CPAP to Improve Menstruation in Women With Polycystic Ovarian Syndrome and Obstructive Sleep Apnea
Withdrawn	`NCT00453219` - FHA: Characterization of Metabolic Status, Brain Circuitry, and Stress-Reactivity	N/A
Completed	`NCT00920634` - Protocol for Drug Use Investigation of Follistim Injection (Study P06132)(COMPLETED)
Recruiting	`NCT06208995` - Quality of Life in Normogonadotropic Anovulation